AnaptysBio Inc

ANAB

Healthcare|Biotechnology|USA

$66.46

-0.20 (-0.30%)

Tangible Book

$0.44

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06041269 A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)	Rheumatoid Arthritis	P2	Active	420	RCT, Double-blind	Rosnilimab, Placebo
NCT06127043 A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)	Ulcerative Colitis	P2	Active	132	RCT, Double-blind	Rosnilimab, Placebo
NCT05205070 A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata	Alopecia Areata	P2	Unknown	45	RCT, Double-blind	Rosnilimab, Placebo
NCT03533751 Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis	Atopic Dermatitis	P2	Completed	302	RCT, Double-blind	Etokimab, Placebo
NCT03614923 Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	Chronic Rhinosinusitis	P2	Completed	105	RCT, Double-blind	Etokimab, Placebo, Mometasone Furoate Nasal Spray
NCT02920021 Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy	Peanut Allergy	P2	Completed	20	RCT, Double-blind	Etokimab, Placebo
NCT05935085 This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).	Atopic Dermatitis Eczema	P2	Terminated	201	RCT, Double-blind	ANB032, Placebo
NCT03469934 Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma	Eosinophilic Asthma	P2	Completed	25	RCT, Double-blind	Etokimab, Placebo
NCT04256044 Analysis of Peripheral Blood ILC2s and Th2 Cells in Response to ANB020	Asthma		Completed	4	—	—